Shire hit by a setback as Hunter syndrome drug fails late-stage study
Shire’s attempt to develop a new formulation of Elaprase that could be used to prevent cognitive decline in patients with rare cases of Hunter syndrome has just slammed into a late-stage wall.
Researchers say the drug, SHP609, failed both the primary as well as key secondary endpoints. The primary focused on a measure of cognition for the children in the study after 12 months of treatment, while the key secondary was an evaluate of the Adaptive Behavior Composite for the drug and control arms.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
